Interim data from the HCV-TARGET study showed that all-oral, direct-acting antiviral (DAA) therapy for hepatitis C (HCV) was highly effective and well tolerated in patients with decompensated cirrhosis. Study findings were presented at The International Liver Congress 2015 in Vienna, Austria.
Sustained virologic response (SVR4) at four weeks was 75% for sofosbuvir/ribavirin; 77% for sofosbuvir/simeprevir; and 81% for sofosbuvir/simeprevir/ribavirin. In addition, short-term follow-up data showed bilirubin and albumin levels also improved when treated with all-oral, DAA antiviral regimens.
Researchers concluded that that all-oral, DAA regimens achieve higher rates of SVR and are better tolerated in HCV patients with decompensated cirrhosis vs. interferon-based therapy. This may be a favorable option to improve liver function for many patients who do not have access to liver transplantation.
For more information visit ilc-congress.eu.